Final report of University Hospital Hradec Kralove to the clinical trial protocol no.B1481038

Abstract

Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Keywords

• Bococizumab (Pf-04950615)
• Cardiovascular Events